Navigation Links
Arena Pharmaceuticals Receives Notice from FDA of Advisory Committee Meeting for Lorcaserin
Date:2/1/2012

erage; and Arena's focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: the timing of regulatory review and approval is uncertain, and the FDA may not complete its review of the resubmission of the lorcaserin NDA by the PDUFA date; the FDA advisory committee meeting for lorcaserin may not be held as expected; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; data and other information related to lorcaserin and Arena's other research and development programs may not meet safety or efficacy requirements or otherwise be sufficient for regulatory review or approval; Arena's submission of a marketing authorization application for regulatory approval of lorcaserin may not be submitted when anticipated, if at all; unexpected or unfavorable new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; having adequate funds; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from collaborators; and satisfactory resolution of
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... Calif. , July 27, 2015 Allergan ... (NASDAQ: KYTH ) today announced that the U.S. ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... acquisition of KYTHERA.  Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO ... of Allergan and KYTHERA filed a Pre-Merger Notification and ...
(Date:7/27/2015)... 2015   Mallinckrodt plc (NYSE: ... today that it has entered into a definitive ... contrast media and delivery systems (CMDS) business to ... at approximately $270 million.   Mallinckrodt,s ... with the company,s stated plan to strategically streamline ...
(Date:7/27/2015)... -- EnzymeBioSystems (OTC BB: ENZB - News) announces that a ... the Company,s lead pharmaceutical product. EnzymeBioSystems plans to seek ... prevention of breast cancer. "We are pleased ... has been completed," stated Gary Rojewski , CEO ... will allow us to move forward in beginning to ...
Breaking Medicine Technology:Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 2Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 3Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 4Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 5Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 6Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 7Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 8Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 9Mallinckrodt Enters Agreement To Sell Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million 2Mallinckrodt Enters Agreement To Sell Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million 3Mallinckrodt Enters Agreement To Sell Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million 4Mallinckrodt Enters Agreement To Sell Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million 5Mallinckrodt Enters Agreement To Sell Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million 6Mallinckrodt Enters Agreement To Sell Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million 7Amooranin Preclinical Sample Batch Completed 2
... Determine How Chest X-Ray CAD Could ... High-Tech Tool for Early Detection, Increased Patient ... and Riverain Medical,today announced the establishment of the ... chest X-ray CAD (computer-aided detection) can improve,practical early ...
... 26 CuraGen Corporation,(Nasdaq: CRGN ), a ... (Copenhagen Stock Exchange: TOPO) announced,today that updated preliminary ... belinostat for T-cell lymphomas, and new preclinical data,evaluating ... presented,at the 2007 American Society of Hematology (ASH) ...
Cached Medicine Technology:Cleveland Clinic Leading Clinical Program to Improve Early-Stage Lung Cancer Detection 2Cleveland Clinic Leading Clinical Program to Improve Early-Stage Lung Cancer Detection 3Cleveland Clinic Leading Clinical Program to Improve Early-Stage Lung Cancer Detection 4Cleveland Clinic Leading Clinical Program to Improve Early-Stage Lung Cancer Detection 5Cleveland Clinic Leading Clinical Program to Improve Early-Stage Lung Cancer Detection 6Cleveland Clinic Leading Clinical Program to Improve Early-Stage Lung Cancer Detection 7CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting 2CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting 3CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting 4CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting 5
(Date:7/27/2015)... ... 27, 2015 , ... BESLER Consulting today announced the publication ... for Medicare and Medicaid Services (CMS) provides each hospital affected by the HRRP ... as the QualityNet Hospital-Specific Report (HSR), this report contains a variety of insights ...
(Date:7/27/2015)... NJ (PRWEB) , ... July 27, 2015 , ... Gary ... Jersey. Dr. Breslow is Founder and Medical Director of The Breslow Center in ... the face, breast, and body in Northern New Jersey. The Breslow Center also ...
(Date:7/27/2015)... ... 27, 2015 , ... For a limited time, Huntington Beach dentist , ... is a great time to change up a look or to simply brighten a ... affect your self-esteem. Over time, the enamel coating can become worn and can expose ...
(Date:7/27/2015)... ... 2015 , ... According to an article published by the Times Free ... Tennessee stemming from intravenous drug use. Intravenous drug use causes more overdoses and is ... diseases including Hepatitis B and C and HIV. Drug treatment facilities in Tennessee have ...
(Date:7/27/2015)... ... July 27, 2015 , ... Hexagon ... new way to understand and share your geospatial experience. These new light-weight applications ... to solve distinct business problems. , “Our world is more dynamic than it ...
Breaking Medicine News(10 mins):Health News:BESLER Consulting Publishes E-book Focused on Reducing Hospital Readmissions 2Health News:NJ Top Doc, Dr. Gary Breslow, has launched Zwivel; a New Online Cosmetic Consultation Service for Doctors and Patients 2Health News:Huntington Beach Cosmetic Dentist, Dr. Rassouli, is Now Offering a Summer Promotion on Zoom Whitening 2Health News:Huntington Beach Cosmetic Dentist, Dr. Rassouli, is Now Offering a Summer Promotion on Zoom Whitening 3Health News:Tennessee Sees an Increase in Hepatitis C Infections from Intravenous Heroin Use 2Health News:Tennessee Sees an Increase in Hepatitis C Infections from Intravenous Heroin Use 3Health News:Hexagon Geospatial Visualizes Stories with the Hexagon Smart M.App® 2Health News:Hexagon Geospatial Visualizes Stories with the Hexagon Smart M.App® 3
... disease, experts say, , , THURSDAY, May 21 (HealthDay ... levels also reduce their risk of heart attack ... have been several conflicting reports about the value ... patients in preventing heart attack and heart disease. ...
... Bayer HealthCare Pharmaceuticals, Inc. today announced that ... 73-4506 (DAST-Inhibitor) will be presented at the 45th Annual ... in Orlando, Florida, May 29 - June 2. ... the oral multi-kinase inhibitor BAY 73-4506 is one of ...
... Omnicare, Inc., which calls itself "the nation,s leading ... to settle Medicaid fraud charges by the State ... had committed Medicaid fraud by illegally switching the ... other facilities. Omnicare,s conduct had originally been ...
... New Method for Optimizing Cardiac Resynchronization Therapy During Exercise. The ... difference in treating CRT patients." Dr. Abraham Kocheril, Professor of ... Illinois at Chicago. , ... Minneapolis-St. ...
... A protein that plays a key role in tumor formation, ... that extends lifespan by dietary restriction. The finding, which appears ... PLoS Genetics , provides a new understanding of how ... scientists new targets for developing and testing drugs that could ...
... and lifestyle characteristics can be linked to different invasive ... presented in the open access journal Breast Cancer ... of the condition are associated with different kinds of ... Research, California, led a team of researchers who used ...
Cached Medicine News:Health News:Strict Blood Sugar Control Lowers Heart Risks in Diabetics 2Health News:Strict Blood Sugar Control Lowers Heart Risks in Diabetics 3Health News:Bayer to Present Data on Development Compound BAY 73-4506 at 45th Annual Meeting of the American Society of Clinical Oncology 2Health News:Bayer to Present Data on Development Compound BAY 73-4506 at 45th Annual Meeting of the American Society of Clinical Oncology 3Health News:National Pharmacy Omnicare Pays 'Unusual' Settlement to Resolve Charges of Generic Drug Switching in Delaware Nursing Homes, Resulting From 'Qui Tam' Lawsuit 2Health News:National Pharmacy Omnicare Pays 'Unusual' Settlement to Resolve Charges of Generic Drug Switching in Delaware Nursing Homes, Resulting From 'Qui Tam' Lawsuit 3Health News:National Pharmacy Omnicare Pays 'Unusual' Settlement to Resolve Charges of Generic Drug Switching in Delaware Nursing Homes, Resulting From 'Qui Tam' Lawsuit 4Health News:National Pharmacy Omnicare Pays 'Unusual' Settlement to Resolve Charges of Generic Drug Switching in Delaware Nursing Homes, Resulting From 'Qui Tam' Lawsuit 5Health News:Heart Rhythm Society Introduced to New Method for Optimizing Cardiac Resynchronization Therapy During Exercise 2Health News:Heart Rhythm Society Introduced to New Method for Optimizing Cardiac Resynchronization Therapy During Exercise 3Health News:Heart Rhythm Society Introduced to New Method for Optimizing Cardiac Resynchronization Therapy During Exercise 4Health News:Key protein may explain the anti-aging and anti-cancer benefits of dietary restriction 2
3.5v Coaxial Ophthalmoscope Set with Convertible Handle and Hard Case. Our 3.5v Coaxial Ophthalmoscope Sets feature high-quality instruments, handles, and cases....
High-quality eyecare from the preferred name in diagnostic instruments....
Our 3.5v Streak or Spot Retinoscope Sets feature instruments with the brightest light output in the industry, reliable handles, and convenient cases....
Our 3.5v Streak or Spot Retinoscope Sets feature instruments with the brightest light output in the industry, reliable handles, and convenient cases....
Medicine Products: